Literature DB >> 8183327

Analyzing expression of the calmodulin and ubiquitin-fusion genes of Trypanosoma cruzi using simultaneous, independent dual gene replacements.

S H Chung1, R D Gillespie, J Swindle.   

Abstract

We describe here a strategy for introducing simultaneous, independent gene replacements into the Trypanosoma cruzi chromosome. The goal of this study was to use two linear DNA fragments to simultaneously replace the CalA2 calmodulin and FUS1 ubiquitin-fusion genes with the neomycin resistance (neo(r)) and chloramphenicol acetyltransferase (CAT) genes, respectively. One clone (D6), of thirty G418-resistant clones analyzed, carried the desired dual gene replacement. CDNA sequence analysis indicated that the CAT mRNA was accurately trans-spliced using the previously identified FUS1 mini-exon addition site. However, DNA sequence analysis of the intergenic sequence immediately upstream of the neo(r) gene in clone D6 identified a mutation which altered the pattern of trans-splicing of the neo(r) mRNA. Possible effects of this mutation on 3' splice acceptor site selection are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8183327     DOI: 10.1016/0166-6851(94)90012-4

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  3 in total

1.  Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors.

Authors:  F S Buckner; J H Griffin; A J Wilson; W C Van Voorhis
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase.

Authors:  F S Buckner; C L Verlinde; A C La Flamme; W C Van Voorhis
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

3.  LYT1 protein is required for efficient in vitro infection by Trypanosoma cruzi.

Authors:  R Manning-Cela; A Cortés; E González-Rey; W C Van Voorhis; J Swindle; A González
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.